Bio-Rad also disclosed during an earnings call that it acquired an undisclosed company that will expand its genomic reagents product portfolio.
The company's full-year revenues rose 6 percent and were slightly higher than the consensus Wall Street estimate.
The firm plans to add more oncology tests, NIPTs and newborn screening assays through in-house development and partnerships with third-party assay makers.
The test is for monitoring treatment response in chronic myeloid leukemia and uses a new Droplet Digital PCR instrument.
The kit, which was launched today, leverages real-time RT-PCR technology to detect and quantify hepatitis C virus-specific RNA with genotypes 1 to 6.
The project builds on a collaboration between Bio-Rad and Genetic Analysis using the GA-map clinical test for gut dysbiosis.
The infringement relates to US patents held by the University of Chicago and exclusively licensed to Bio-Rad.
The contract covers Bio-Rad's iQ-Check RT-PCR pathogen detection test kits, which cover pathogens including Salmonella spp. and Listeria monocytogenes.
Researchers tie a variant in ADAMTS3 to breathing difficulties in dissimilar dog breeds, according to Discover's D-brief blog.
The Japan Times reports that researchers sequenced the genome of a woman who lived during the Jomon period.
Parents of children with rare genetic disease have to contend with shifts in the interpretation of genetic variants, the Wall Street Journal reports.
In Science this week: single-nucleus RNA sequencing of brain tissue from individuals with autism, and more.